Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2014
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Alcobra
- 16 Dec 2013 Primary endpoint 'Test-of-Variables-of-Attention' has been met.
- 15 Dec 2013 Results published in the Media Release.
- 01 Dec 2013 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History